Enliven Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 0.01, 0.01, 48.81, 249.03 ], "ebit_estimate": [ -132.1, -177.16, -236.45, -258.42, -179.39 ], "ebitda_estimate": [ -126.72, -171, -249, null, null ], "net_income_estimate": [ -114.78, -161.62, -221.62, -243.6, -119.63 ], "per_share_eps_estimate": [ -1.75, -2.37, -3.01, -3.31, -2.12 ], "eps_nri_estimate": [ -1.77, -2.39, -3.14, -3.29, -2.12 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -116.19, -161.62, -221.62, -243.6, -117.79 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, 62.33, 49 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -21.14, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -19.74, "future_eps_nri_estimate_growth": -21.14, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -26.32, "future_ebitda_estimate_growth": -28.46, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -29.96, "future_pretax_income_estimate_growth": -29.8, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -30.35, -34.25, -39.69, -40, -48, -53, -58 ], "ebitda_estimate": [ -29.79, -31.5, -37.6, -37, null, null, null ], "net_income_estimate": [ -26.29, -29.86, -35.46, -39.2, -44.6, -49.9, -53.3 ], "per_share_eps_estimate": [ -0.4, -0.44, -0.53, -0.55, -0.61, -0.67, -0.73 ], "eps_nri_estimate": [ -0.4, -0.45, -0.54, -0.54, -0.61, -0.67, -0.73 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -26.75, -30.23, -35.74, -31.41, -44.6, -41.17, -53.3 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -21.14, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -19.74, "future_eps_nri_estimate_growth": -21.14, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -26.32, "future_ebitda_estimate_growth": -28.46, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -29.96, "future_pretax_income_estimate_growth": -29.8, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }